Anticoagulation Management for Pulmonary Embolism in Patients with Active Malignancy Starting Immunotherapy

Primary Recommendation: LMWH as First-Line

The National Comprehensive Cancer Network recommends low-molecular-weight heparin (LMWH) as the preferred anticoagulant for cancer-associated venous thromboembolism (VTE), with dalteparin being the only LMWH with FDA approval specifically for this indication, based on the highest quality evidence 1, 2, 3
Dalteparin dosing is recommended at 200 IU/kg subcutaneously once daily for the first month, followed by 150 IU/kg once daily, with a Category 1 recommendation 2, 4
The CLOT trial demonstrated that LMWH prevented more VTE recurrences than warfarin in cancer patients without increasing serious bleeding, supporting the use of LMWH as first-line therapy 1
Multiple guidelines, including those from the American College of Chest Physicians and the European Society of Medical Oncology, uniformly recommend LMWH over vitamin K antagonists for cancer-associated thrombosis 1, 5, 6

If the patient refuses or has compelling reasons to avoid LMWH injections, DOACs are acceptable alternatives, with rivaroxaban being the preferred DOAC option 2, 3, 4
Rivaroxaban dosing is recommended at 15 mg orally twice daily for 21 days, then 20 mg once daily, and can be started immediately without parenteral lead-in 2, 8
Apixaban is an alternative DOAC option, with dosing at 10 mg orally twice daily for 7 days, then 5 mg twice daily, and may be preferred over rivaroxaban in patients with GI malignancies if DOAC is necessary 2, 4
Edoxaban requires 5-10 days of parenteral anticoagulation first and should be avoided in gastrointestinal cancer 3, 4

Absolute contraindications to DOACs in this population include gastrointestinal or gastroesophageal malignancies, severe renal impairment (creatinine clearance <30 mL/min), and triple-positive antiphospholipid syndrome, with LMWH being the preferred alternative 4, 7, 9
Renal function considerations are crucial, with CrCl <30 mL/min requiring the use of unfractionated heparin (UFH) instead of LMWH, and UFH dosing at 80 units/kg IV bolus, then 18 units/kg/hour infusion, adjusted to aPTT 1.5-2.5 times control 8, 9

Anticoagulation should be continued indefinitely as long as cancer remains active, with the initial treatment phase lasting 3-6 months at full therapeutic doses, and the extended phase continuing until cancer is cured or no evidence of active disease 1, 5, 9
Active cancer is defined as any evidence on imaging or any cancer treatment (surgery, radiation, chemotherapy, immunotherapy) within the past 6 months, and patients starting immunotherapy represent ongoing active cancer requiring extended anticoagulation 1, 9

Assess renal function immediately, with CrCl ≥30 mL/min proceeding with LMWH or DOAC, and CrCl <30 mL/min requiring the use of UFH 8, 9
Identify cancer type, with GI/gastroesophageal malignancy requiring LMWH only (dalteparin preferred), and non-GI malignancy allowing for LMWH or DOACs 4, 9
Initiate anticoagulation immediately, without delaying for diagnostic confirmation if clinical probability is high, and start while awaiting imaging results 8, 9

Do not use warfarin as first-line therapy in cancer patients, due to drug interactions with chemotherapy and immunotherapy causing INR fluctuations, higher VTE recurrence rates, and higher bleeding risk compared to LMWH 1, 5, 9
Do not stop anticoagulation at 3 months, as cancer-associated VTE requires extended therapy, and recurrence risk remains elevated throughout active cancer treatment 9
Do not use thrombolysis routinely, reserving it only for hemodynamically unstable PE with shock, and not indicating it for stable PE even with RV dysfunction 6, 9
Do not place IVC filter prophylactically, only indicating it for absolute contraindication to anticoagulation or recurrent VTE despite adequate anticoagulation 7, 9